| 1 | RAD51 Testing in Patients with Early HER2-Negative Breast Cancer and Homologous Recombination Deficiency: A
Post Hoc
Analysis of the GeparOLA Trial | 6.8 | 2 | Citations (PDF) |
| 2 | Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD—Long-term Survival of the GeparOLA Study | 6.8 | 3 | Citations (PDF) |
| 3 | Switching to T-DM1 remains justified in patients with HER2-negative residual invasive breast cancer after neoadjuvant therapy | 2.3 | 1 | Citations (PDF) |
| 4 | Impact of the ONCOBIOME network in cancer microbiome research | 33.0 | 16 | Citations (PDF) |
| 5 | Body mass index and weight changes in patients with HER2-positive early breast cancer: A sub-analysis of the APHINITY trial | 5.0 | 5 | Citations (PDF) |
| 6 | Effects of pregnancy on breast cancer immunology: immune biomarker and TIL quantification | 6.4 | 1 | Citations (PDF) |
| 7 | The association of high body mass index with the safety and efficacy of sacituzumab govitecan in patients with metastatic triple-negative breast cancer from the ASCENT study | 5.3 | 2 | Citations (PDF) |
| 8 | Artificial intelligence as treatment support in breast cancer: current perspectives | 2.3 | 6 | Citations (PDF) |
| 9 | Image‐based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno‐oncology Biomarker Working Group on Breast Cancer | 4.9 | 17 | Citations (PDF) |
| 10 | Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression | 16.9 | 143 | Citations (PDF) |
| 11 | An Analysis of
PIK3CA
Hotspot Mutations and Response to Neoadjuvant Therapy in Patients with Breast Cancer from Four Prospective Clinical Trials | 6.8 | 9 | Citations (PDF) |
| 12 | Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial | 16.9 | 9 | Citations (PDF) |
| 13 | GAIN2 trial overall survival with intense versus tailored dose dense chemotherapy in early breast cancer | 6.4 | 1 | Citations (PDF) |
| 14 | Adjuvant Pertuzumab and Trastuzumab in Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer in the APHINITY Trial: Third Interim Overall Survival Analysis With Efficacy Update | 16.9 | 21 | Citations (PDF) |
| 15 | Shifting the Paradigm: The Transformative Role of Neoadjuvant Therapy in Early Breast Cancer | 3.8 | 8 | Citations (PDF) |
| 16 | Window of opportunity trials with immune checkpoint inhibitors in triple-negative breast cancer | 5.3 | 13 | Citations (PDF) |
| 17 | Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109) | 4.8 | 4 | Citations (PDF) |
| 18 | Chemotherapy in older patients with early breast cancer | 2.3 | 12 | Citations (PDF) |
| 19 | Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer | 5.0 | 5 | Citations (PDF) |
| 20 | Health-related quality of life in the phase III ASCENT trial of sacituzumab govitecan versus standard chemotherapy in metastatic triple-negative breast cancer | 5.0 | 46 | Citations (PDF) |
| 21 | Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT | 16.9 | 56 | Citations (PDF) |
| 22 | Personalized medicine—from translational research to clinical practice | 0.1 | 0 | Citations (PDF) |
| 23 | Inferred Immune-Cell Activity Is an Independent Predictor of HER2-Negative Breast Cancer Prognosis and Response to Paclitaxel-Based Therapy in the GeparSepto Trial | 6.8 | 7 | Citations (PDF) |
| 24 | Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer | 6.8 | 42 | Citations (PDF) |
| 25 | Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial | 5.0 | 28 | Citations (PDF) |
| 26 | SA 11.1 Post-menopausal: Who needs chemotherapy in the neo (adjuvant) setting? | 2.3 | 0 | Citations (PDF) |
| 27 | SA 9.2 Optimal systemic therapy for residual disease in TNBC | 2.3 | 0 | Citations (PDF) |
| 28 | The effect of denosumab on disseminated tumor cells (DTCs) of breast cancer patients with neoadjuvant treatment: a GeparX translational substudy | 4.8 | 8 | Citations (PDF) |
| 29 | Identifying breast cancer patients at risk of relapse despite pathological complete response after neoadjuvant therapy | 6.4 | 30 | Citations (PDF) |
| 30 | Caveolin Gene Expression Predicts Clinical Outcomes for Early-Stage HER2-Negative Breast Cancer Treated with Paclitaxel-Based Chemotherapy in the GeparSepto Trial | 6.8 | 6 | Citations (PDF) |
| 31 | Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel | 3.8 | 3 | Citations (PDF) |
| 32 | Poor Outcome in Postpartum Breast Cancer Patients Is Associated with Distinct Molecular and Immunologic Features | 6.8 | 9 | Citations (PDF) |
| 33 | Personalized medicine—from translational research to clinical practice | 0.0 | 0 | Citations (PDF) |
| 34 | Pitfalls in machine learning‐based assessment of tumor‐infiltrating lymphocytes in breast cancer: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer | 4.9 | 46 | Citations (PDF) |
| 35 | Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno‐Oncology Biomarker Working Group on Breast Cancer | 4.9 | 40 | Citations (PDF) |
| 36 | RANK Expression as an Independent Predictor for Response to Neoadjuvant Chemotherapy in Luminal-Like Breast Cancer: A Translational Insight from the GeparX Trial | 6.8 | 5 | Citations (PDF) |
| 37 | The CDK4/6 inhibitor revolution — a game-changing era for breast cancer treatment | 70.8 | 228 | Citations (PDF) |
| 38 | Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer | 5.0 | 29 | Citations (PDF) |
| 39 | Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer | 6.8 | 34 | Citations (PDF) |
| 40 | Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients | 5.0 | 27 | Citations (PDF) |
| 41 | Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial | 5.0 | 15 | Citations (PDF) |
| 42 | mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease | 4.3 | 11 | Citations (PDF) |
| 43 | Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study | 6.8 | 185 | Citations (PDF) |
| 44 | Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted Therapy | 4.6 | 5 | Citations (PDF) |
| 45 | Understanding the barriers to, and facilitators of, ovarian toxicity assessment in breast cancer clinical trials | 2.3 | 6 | Citations (PDF) |
| 46 | Outcome of breast cancer patients treated with chemotherapy during pregnancy compared with non-pregnant controls | 5.0 | 32 | Citations (PDF) |
| 47 | Integrating Immunotherapy Into the Treatment Landscape for Patients With Triple-Negative Breast Cancer | 4.5 | 13 | Citations (PDF) |
| 48 | Sacituzumab Govitecan: Past, Present and Future of a New Antibody–Drug Conjugate and Future Horizon | 2.3 | 34 | Citations (PDF) |
| 49 | Physical activity, sedentary time and breast cancer risk: a Mendelian randomisation study | 10.6 | 68 | Citations (PDF) |
| 50 | An Overview of Clinical Development of Agents for Metastatic or Advanced Breast Cancer Without ERBB2 Amplification (HER2-Low) | 14.4 | 32 | Citations (PDF) |
| 51 | Management onkologischer Erkrankungen in der Schwangerschaft | 0.2 | 0 | Citations (PDF) |
| 52 | Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE | 6.4 | 37 | Citations (PDF) |
| 53 | Schwangerschaft nach Krebs | 0.2 | 0 | Citations (PDF) |
| 54 | Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor–positive Early Breast Cancer: Results from the SOLE Trial | 6.8 | 8 | Citations (PDF) |
| 55 | Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox | 27.4 | 75 | Citations (PDF) |
| 56 | Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer | 6.8 | 42 | Citations (PDF) |
| 57 | Gene Expression–Based Prediction of Neoadjuvant Chemotherapy Response in Early Breast Cancer: Results of the Prospective Multicenter EXPRESSION Trial | 6.8 | 20 | Citations (PDF) |
| 58 | Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study | 27.4 | 234 | Citations (PDF) |
| 59 | Integrating CDK 4-6 in the treatment of patients with early breast cancer | 2.3 | 1 | Citations (PDF) |
| 60 | Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer | 34.6 | 1,420 | Citations (PDF) |
| 61 | Efficacy of Endocrine Therapy for the Treatment of Breast Cancer in Men | 14.4 | 44 | Citations (PDF) |
| 62 | Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment | 13.3 | 141 | Citations (PDF) |
| 63 | Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline | 16.9 | 901 | Citations (PDF) |
| 64 | Breast cancer | 62.4 | 1,441 | Citations (PDF) |
| 65 | Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus | 0.4 | 6 | Citations (PDF) |
| 66 | Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial | 16.9 | 290 | Citations (PDF) |
| 67 | Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors – An analysis of 2765 patients from neoadjuvant clinical trials | 5.0 | 78 | Citations (PDF) |
| 68 | Frühes Mammakarzinom: Aktuelle Strategien in der System- und Radiotherapie | 0.1 | 0 | Citations (PDF) |
| 69 | Adjuvant Olaparib for Patients with
BRCA1
- or
BRCA2
-Mutated Breast Cancer | 34.6 | 1,464 | Citations (PDF) |
| 70 | Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative | 25.2 | 157 | Citations (PDF) |
| 71 | Chemotherapy-induced ovarian failure in young women with early breast cancer: Prospective analysis of four randomised neoadjuvant/adjuvant breast cancer trials | 5.0 | 34 | Citations (PDF) |
| 72 | A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy | 2.4 | 7 | Citations (PDF) |
| 73 | Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials | 27.4 | 471 | Citations (PDF) |
| 74 | Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials | 27.4 | 296 | Citations (PDF) |
| 75 | Breast cancer diagnosed in the post-weaning period is indicative for a poor outcome | 5.0 | 17 | Citations (PDF) |
| 76 | A Plain Language Summary of the ASCENT Study: Sacituzumab Govitecan for Metastatic Triple-Negative Breast Cancer | 2.3 | 12 | Citations (PDF) |
| 77 | Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer | 14.4 | 44 | Citations (PDF) |
| 78 | Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 | 10.0 | 691 | Citations (PDF) |
| 79 | The journey of tumor-infiltrating lymphocytes as a biomarker in breast cancer: clinical utility in an era of checkpoint inhibition | 10.0 | 218 | Citations (PDF) |
| 80 | Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2) | 5.0 | 17 | Citations (PDF) |
| 81 | AGO Recommendations for the Surgical Therapy of the Axilla After Neoadjuvant Chemotherapy: 2021 Update | 0.4 | 23 | Citations (PDF) |
| 82 | THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR+), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2–) ADVANCED BREAST CANCER (ABC) | 2.3 | 0 | Citations (PDF) |
| 83 | AGO Algorithms for the Treatment of Breast Cancer: Update 2021 | 0.4 | 9 | Citations (PDF) |
| 84 | The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group | 6.4 | 229 | Citations (PDF) |
| 85 | Mammakarzinom-Studie OlympiA: Folgen für die Versorgung 2021, , | | 0 | Citations (PDF) |
| 86 | Neutropenic complications in the PANTHER phase III study of adjuvant tailored dose-dense chemotherapy in early breast cancer | 1.8 | 13 | Citations (PDF) |
| 87 | Early assessment with magnetic resonance imaging for prediction of pathologic response to neoadjuvant chemotherapy in triple-negative breast cancer: Results from the phase III BrighTNess trial | 0.9 | 11 | Citations (PDF) |
| 88 | Breast Conservation After Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer | 8.8 | 131 | Citations (PDF) |
| 89 | Reactive stroma and trastuzumab resistance in HER2‐positive early breast cancer | 4.3 | 20 | Citations (PDF) |
| 90 | Efficacy and safety of tailored and dose‐dense adjuvant chemotherapy and trastuzumab for resected HER2‐positive breast cancer: Results from the phase 3 PANTHER trial | 4.0 | 22 | Citations (PDF) |
| 91 | Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial | 62.4 | 202 | Citations (PDF) |
| 92 | Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer | 34.6 | 1,147 | Citations (PDF) |
| 93 | Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial | 4.0 | 35 | Citations (PDF) |
| 94 | MGMT promoter methylation in triple negative breast cancer of the GeparSixto trial | 2.3 | 11 | Citations (PDF) |
| 95 | Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis | 0.4 | 5 | Citations (PDF) |
| 96 | Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer | 6.4 | 171 | Citations (PDF) |
| 97 | Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial | 16.9 | 488 | Citations (PDF) |
| 98 | A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial | 6.8 | 14 | Citations (PDF) |
| 99 | The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers in breast cancer clinical trials and daily practice | 4.9 | 191 | Citations (PDF) |
| 100 | Patient‐reported outcomes from KATHERINE: A phase 3 study of adjuvant trastuzumab emtansine versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for human epidermal growth factor receptor 2–positive breast cancer | 4.0 | 25 | Citations (PDF) |
| 101 | Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study | 6.8 | 56 | Citations (PDF) |
| 102 | PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy | 3.3 | 47 | Citations (PDF) |
| 103 | Schwangerschaft nach einer Tumorerkrankung | 0.1 | 1 | Citations (PDF) |
| 104 | Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials | 2.3 | 40 | Citations (PDF) |
| 105 | Fatal events during clinical trials: an evaluation of deaths during breast cancer studies | 2.0 | 1 | Citations (PDF) |
| 106 | Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy | 0.4 | 2 | Citations (PDF) |
| 107 | Breast Cancer in Young and Premenopausal Women | 10.0 | 0 | Citations (PDF) |
| 108 | The Rise of Oncology Biosimilars: From Process to Promise | 2.3 | 12 | Citations (PDF) |
| 109 | Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis | 1.1 | 81 | Citations (PDF) |
| 110 | Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trial | 4.3 | 13 | Citations (PDF) |
| 111 | Diagnosis and Therapy of Triple-Negative Breast Cancer (TNBC) – Recommendations for Daily Routine Practice | 0.4 | 34 | Citations (PDF) |
| 112 | Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial | 2.4 | 12 | Citations (PDF) |
| 113 | Breast cancer, placenta and pregnancy | 5.0 | 33 | Citations (PDF) |
| 114 | Alpelisib for
PIK3CA
-Mutated, Hormone Receptor–Positive Advanced Breast Cancer | 34.6 | 2,393 | Citations (PDF) |
| 115 | Development of central nervous system metastases as a first site of metastatic disease in breast cancer patients treated in the neoadjuvant trials GeparQuinto and GeparSixto | 4.8 | 17 | Citations (PDF) |
| 116 | Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy | 16.9 | 180 | Citations (PDF) |
| 117 | Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial | 6.8 | 43 | Citations (PDF) |
| 118 | Genome-wide association study of germline variants and breast cancer-specific mortality | 5.5 | 62 | Citations (PDF) |
| 119 | Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials | 62.4 | 358 | Citations (PDF) |
| 120 | Androgen receptor expression and response to chemotherapy in breast cancer patients treated in the neoadjuvant TECHNO and PREPARE trial | 5.5 | 21 | Citations (PDF) |
| 121 | Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy | 4.8 | 33 | Citations (PDF) |
| 122 | Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes | 6.5 | 1,013 | Citations (PDF) |
| 123 | Tamoxifen treatment for male breast cancer and risk of thromboembolism: prospective cohort analysis | 5.5 | 38 | Citations (PDF) |
| 124 | Knowledge, attitudes and practice of physicians towards fertility and pregnancy-related issues in youngBRCA-mutated breast cancer patients | 2.7 | 35 | Citations (PDF) |
| 125 | Intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for neoadjuvant treatment of high-risk early breast cancer (GeparOcto—GBG 84): A randomised phase III trial | 5.0 | 102 | Citations (PDF) |
| 126 | Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer | 34.6 | 2,315 | Citations (PDF) |
| 127 | Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis | 4.9 | 95 | Citations (PDF) |
| 128 | Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial | 27.4 | 695 | Citations (PDF) |
| 129 | Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor | 6.8 | 17 | Citations (PDF) |
| 130 | Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials | 27.4 | 978 | Citations (PDF) |
| 131 | Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy | 27.4 | 1,897 | Citations (PDF) |
| 132 | Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial | 27.4 | 106 | Citations (PDF) |
| 133 | Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data | 16.9 | 357 | Citations (PDF) |
| 134 | Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer | 0.4 | 74 | Citations (PDF) |
| 135 | Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | 34.6 | 1,121 | Citations (PDF) |
| 136 | The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial | 25.2 | 574 | Citations (PDF) |
| 137 | The BCY3/BCC 2017 survey on physicians' knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients | 2.3 | 89 | Citations (PDF) |
| 138 | Tyrosine kinase inhibitors for brain metastases in HER2-positive breast cancer | 9.6 | 80 | Citations (PDF) |
| 139 | Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature | 3.4 | 19 | Citations (PDF) |
| 140 | Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC) | 1.6 | 22 | Citations (PDF) |
| 141 | A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer | 25.2 | 229 | Citations (PDF) |
| 142 | pCR rates in patients with bilateral breast cancer after neoadjuvant anthracycline-taxane based-chemotherapy – A retrospective pooled analysis of individual patients data of four German neoadjuvant trials | 2.3 | 7 | Citations (PDF) |
| 143 | Using ultrasound and palpation for predicting axillary lymph node status following neoadjuvant chemotherapy – Results from the multi-center SENTINA trial | 2.3 | 64 | Citations (PDF) |
| 144 | Reply to the letter to the editor ‘Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study’ by Daly et al. | 10.0 | 0 | Citations (PDF) |
| 145 | Sixteen months follow-up of health related quality of life in women with high-risk breast cancer after random assignment to adjuvant treatment with tailored dose-dense chemotherapy vs standard three-weekly adjuvant chemotherapy (PANTHER study) | 5.0 | 0 | Citations (PDF) |
| 146 | Restricted Axillary Staging in Clinically and Sonographically Node-Negative Early Invasive Breast Cancer (c/iT1–2) in the Context of Breast Conserving Therapy: First Results Following Commencement of the Intergroup-Sentinel-Mamma (INSEMA) Trial | 0.4 | 136 | Citations (PDF) |
| 147 | Efficacy and safety of nab-paclitaxel 125 mg/m2 and nab-paclitaxel 150 mg/m2 compared to paclitaxel in early high-risk breast cancer. Results from the neoadjuvant randomized GeparSepto study (GBG 69) | 2.4 | 24 | Citations (PDF) |
| 148 | HER2-positive breast cancer | 62.4 | 997 | Citations (PDF) |
| 149 | Advances in the treatment of advanced oestrogen-receptor-positive breast cancer | 62.4 | 192 | Citations (PDF) |
| 150 | Association analysis identifies 65 new breast cancer risk loci | 38.0 | 1,420 | Citations (PDF) |
| 151 | Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer | 25.2 | 403 | Citations (PDF) |
| 152 | Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE) | 5.0 | 98 | Citations (PDF) |
| 153 | Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer | 14.4 | 348 | Citations (PDF) |
| 154 | Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) | 5.0 | 18 | Citations (PDF) |
| 155 | Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors | 2.3 | 738 | Citations (PDF) |
| 156 | Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research | 2.3 | 628 | Citations (PDF) |
| 157 | Prognostic Impact of Circulating Tumor Cells for Breast Cancer Patients Treated in the Neoadjuvant "Geparquattro" Trial | 6.8 | 105 | Citations (PDF) |
| 158 | Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results | 3.4 | 133 | Citations (PDF) |
| 159 | Clinical relevance and concordance of HER2 status in local and central testing—an analysis of 1581 HER2-positive breast carcinomas over 12 years | 4.8 | 30 | Citations (PDF) |
| 160 | Outcome after neoadjuvant chemotherapy in estrogen receptor-positive and progesterone receptor-negative breast cancer patients: a pooled analysis of individual patient data from ten prospectively randomized controlled neoadjuvant trials | 2.4 | 43 | Citations (PDF) |
| 161 | Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer | 2.4 | 8 | Citations (PDF) |
| 162 | Model-based optimization of G-CSF treatment during cytotoxic chemotherapy | 2.3 | 8 | Citations (PDF) |
| 163 | Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group | 4.8 | 282 | Citations (PDF) |
| 164 | Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer | 6.8 | 182 | Citations (PDF) |
| 165 | Loss of
ARID1A
Activates
ANXA1
, which Serves as a Predictive Biomarker for Trastuzumab Resistance | 6.8 | 57 | Citations (PDF) |
| 166 | Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer | 16.6 | 91 | Citations (PDF) |
| 167 | Dual Blockade of HER-2 Provides a Greater Magnitude of Benefit in Patients With Hormone-Negative Versus Hormone-Positive Breast Cancer | 2.3 | 11 | Citations (PDF) |
| 168 | Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy | 5.0 | 66 | Citations (PDF) |
| 169 | Integrated Analysis of PTEN and p4EBP1 Protein Expression as Predictors for pCR in HER2-Positive Breast Cancer | 6.8 | 47 | Citations (PDF) |
| 170 | Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto—GBG 69): a randomised, phase 3 trial | 27.4 | 377 | Citations (PDF) |
| 171 | Taxanes in the treatment of breast cancer: Have we better defined their role in older patients? A position paper from a SIOG Task Force | 9.6 | 54 | Citations (PDF) |
| 172 | Second international consensus guidelines for breast cancer in young women (BCY2) | 2.3 | 151 | Citations (PDF) |
| 173 | Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma | 2.9 | 2 | Citations (PDF) |
| 174 | Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): aktueller Stand des retrospektiven und prospektiven Forschungsprogramms | 0.0 | 0 | Citations (PDF) |
| 175 | Brain Metastases in Breast Cancer Network Germany (BMBC, GBG 79): aktueller Stand und Analyse der Patientendaten des Hirnmetastasenregisters | 0.4 | 0 | Citations (PDF) |
| 176 | Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study | 4.3 | 34 | Citations (PDF) |
| 177 | Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer | 34.6 | 1,497 | Citations (PDF) |
| 178 | Targeting the Immune System in Breast Cancer: Hype or Hope?: TILs and Newer Immune-Based Therapies Being Evaluated for HER2+ and TNBC | 0.8 | 3 | Citations (PDF) |
| 179 | Impact of body mass index on neoadjuvant treatment outcome: a pooled analysis of eight prospective neoadjuvant breast cancer trials | 2.4 | 108 | Citations (PDF) |
| 180 | Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials | 2.4 | 105 | Citations (PDF) |
| 181 | Breast Cancer Diagnosed During Pregnancy | 14.4 | 209 | Citations (PDF) |
| 182 | Dual Blockade with AFatinib and Trastuzumab as NEoadjuvant Treatment for Patients with Locally Advanced or Operable Breast Cancer Receiving Taxane–Anthracycline Containing Chemotherapy—DAFNE (GBG-70) | 6.8 | 40 | Citations (PDF) |
| 183 | Neoadjuvant treatment of breast cancer | 1.8 | 20 | Citations (PDF) |
| 184 | A randomized phase 2 study comparing EC or CMF versus nab‐paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high‐risk early breast cancer (ICE II‐GBG 52) | 4.0 | 55 | Citations (PDF) |
| 185 | Classical pathology and mutational load of breast cancer – integration of two worlds | 3.3 | 102 | Citations (PDF) |
| 186 | Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques | 5.5 | 99 | Citations (PDF) |
| 187 | Standardized Ki67 Diagnostics Using Automated Scoring—Clinical Validation in the GeparTrio Breast Cancer Study | 6.8 | 96 | Citations (PDF) |
| 188 | Sentinel Lymph Node Biopsy for Breast Cancer Treatment During Pregnancy - on Behalf of the International Network of Cancer, Infertility and Pregnancy (Incip) and the German Breast Group (Gbg) | 10.0 | 4 | Citations (PDF) |
| 189 | Does Toxicity Predict Efficacy? Insight Into the Mechanism of Action of Lapatinib | 16.9 | 10 | Citations (PDF) |
| 190 | Current Perspectives on HER2-Positive BC | 0.0 | 0 | Citations (PDF) |
| 191 | Monounsaturated fatty acids in serum triacylglycerols are associated with response to neoadjuvant chemotherapy in breast cancer patients | 4.3 | 46 | Citations (PDF) |
| 192 | Analysis of PIK3CA Mutations in Breast Cancer Subtypes | 1.0 | 54 | Citations (PDF) |
| 193 | Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis | 62.4 | 4,264 | Citations (PDF) |
| 194 | Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma | 2.4 | 107 | Citations (PDF) |
| 195 | First international consensus guidelines for breast cancer in young women (BCY1) | 2.3 | 154 | Citations (PDF) |
| 196 | Surgical treatment of primary breast cancer in the neoadjuvant setting | 0.3 | 62 | Citations (PDF) |
| 197 | Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes | 2.9 | 79 | Citations (PDF) |
| 198 | Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial | 2.4 | 116 | Citations (PDF) |
| 199 | RANK expression as a prognostic and predictive marker in breast cancer | 2.4 | 65 | Citations (PDF) |
| 200 | Surgical Outcome after Neoadjuvant Chemotherapy and Bevacizumab: Results from the GeparQuinto Study (GBG 44) | 2.3 | 27 | Citations (PDF) |
| 201 | Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial | 27.4 | 954 | Citations (PDF) |
| 202 | Phase III study on efficacy of taxanes plus bevacizumab with or without capecitabine as first-line chemotherapy in metastatic breast cancer | 2.4 | 19 | Citations (PDF) |
| 203 | Impact of Multifocal or Multicentric Disease on Surgery and Locoregional, Distant and Overall Survival of 6,134 Breast Cancer Patients Treated With Neoadjuvant Chemotherapy | 2.3 | 91 | Citations (PDF) |
| 204 | Brain Metastases in Breast Cancer Network Germany (BMBC): Eine multizentrische retrospektive und prospektive Datenbank und Biomaterialsammlung von Patientinnen mit Hirnmetastasen eines Mammakarzinoms | 0.0 | 0 | Citations (PDF) |
| 205 | Brain Metastases in Breast Cancer Network Germany (BMBC): Eine multizentrische retrospektive und prospektive Datenbank und Biomaterialsammlung von Patientinnen mit Hirnmetastasen eines Mammakarzinoms | 0.4 | 0 | Citations (PDF) |
| 206 | Capecitabine plus paclitaxel versus epirubicin plus paclitaxel as first-line treatment for metastatic breast cancer: efficacy and safety results of a randomized, phase III trial by the AGO Breast Cancer Study Group | 2.4 | 23 | Citations (PDF) |
| 207 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 | 10.0 | 3,350 | Citations (PDF) |
| 208 | Everolimus as treatment for breast cancer patients with bone metastases only: results of the phase II RADAR study | 2.3 | 32 | Citations (PDF) |
| 209 | Breakthroughs in research and treatment of early breast cancer: an overview of the last three decades | 1.9 | 10 | Citations (PDF) |
| 210 | Neoadjuvant chemotherapy with paclitaxel and everolimus in breast cancer patients with non-responsive tumours to epirubicin/cyclophosphamide (EC)±bevacizumab – Results of the randomised GeparQuinto study (GBG 44) | 5.0 | 80 | Citations (PDF) |
| 211 | Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer | 2.3 | 13 | Citations (PDF) |
| 212 | Update on neoadjuvant/preoperative therapy of breast cancer | 1.8 | 20 | Citations (PDF) |
| 213 | Ki67 Measured after Neoadjuvant Chemotherapy for Primary Breast Cancer | 6.8 | 160 | Citations (PDF) |
| 214 | Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial | 2.3 | 200 | Citations (PDF) |
| 215 | Neoadjuvant Chemotherapy in Women 35 and Under | 0.0 | 1 | Citations (PDF) |
| 216 | 8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy | 10.0 | 1 | Citations (PDF) |
| 217 | The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy | 10.0 | 308 | Citations (PDF) |
| 218 | Predictive value of HER2 serum levels in patients treated with lapatinib or trastuzumab – a translational project in the neoadjuvant GeparQuinto trial | 5.5 | 35 | Citations (PDF) |
| 219 | Thymosin beta 15A (TMSB15A) is a predictor of chemotherapy response in triple-negative breast cancer | 5.5 | 27 | Citations (PDF) |
| 220 | Breast cancer in pregnancy | 62.4 | 254 | Citations (PDF) |
| 221 | Treatment of breast cancer during pregnancy: an observational study | 27.4 | 247 | Citations (PDF) |
| 222 | Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA) | 27.4 | 543 | Citations (PDF) |
| 223 | Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial | 27.4 | 443 | Citations (PDF) |
| 224 | Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer | 34.6 | 500 | Citations (PDF) |
| 225 | Integration of Metabolomics and Expression of Glycerol-3-phosphate Acyltransferase (GPAM) in Breast Cancer—Link to Patient Survival, Hormone Receptor Status, and Metabolic Profiling | 3.4 | 74 | Citations (PDF) |
| 226 | Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy as First-Line Treatment for Advanced Breast Cancer: The GEICAM/GBG Lea Study. Safety Analysis | 10.0 | 0 | Citations (PDF) |
| 227 | Impact of Multifocal or Multicentric Disease on Surgical, Locoregional, and Distant Survival After Neoadjuvant Chemotherapy in 3562 Breast Cancer Patients | 10.0 | 0 | Citations (PDF) |
| 228 | Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors | 5.0 | 16 | Citations (PDF) |
| 229 | Neoadjuvant Clinical Trials for the Treatment of Primary Breast Cancer: The Experience of the German Study Groups | 4.2 | 4 | Citations (PDF) |
| 230 | Bevacizumab Treatment for Advanced Breast Cancer | 3.4 | 34 | Citations (PDF) |
| 231 | Lessons from the neoadjuvant setting on how best to choose adjuvant therapies | 2.3 | 22 | Citations (PDF) |
| 232 | Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy | 2.4 | 198 | Citations (PDF) |
| 233 | Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy | 8.1 | 22 | Citations (PDF) |
| 234 | Incorporating Agents that Target HER2 in the Neoadjuvant Setting | 0.8 | 0 | Citations (PDF) |
| 235 | Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis | 2.9 | 110 | Citations (PDF) |
| 236 | The GISS Trial: a Phase II Prevention Trial of Screening Plus Goserelin, Ibandronate, versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer | 1.1 | 7 | Citations (PDF) |
| 237 | Novel Theranostic Opportunities Offered by Characterization of Altered Membrane Lipid Metabolism in Breast Cancer Progression | 3.8 | 508 | Citations (PDF) |
| 238 | Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—results from the GeparQuattro study (GBG 40) | 2.4 | 59 | Citations (PDF) |
| 239 | Mammakarzinom - Fallbericht einer Patientin, randomisiert zu Letrozol + Bevacizumab im Rahmen der LEA-Studie | 0.0 | 0 | Citations (PDF) |
| 240 | Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial | 2.4 | 51 | Citations (PDF) |
| 241 | Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study | 2.4 | 263 | Citations (PDF) |
| 242 | A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies | 10.0 | 59 | Citations (PDF) |
| 243 | Detection and HER2 Expression of Circulating Tumor Cells: Prospective Monitoring in Breast Cancer Patients Treated in the Neoadjuvant GeparQuattro Trial | 6.8 | 484 | Citations (PDF) |
| 244 | Capecitabine in Addition to Anthracycline- and Taxane-Based Neoadjuvant Treatment in Patients With Primary Breast Cancer: Phase III GeparQuattro Study | 16.9 | 205 | Citations (PDF) |
| 245 | nab-Paclitaxel in patients with advanced solid tumors and hepatic dysfunction: a pilot study | 2.6 | 14 | Citations (PDF) |
| 246 | Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer | 16.9 | 1,624 | Citations (PDF) |
| 247 | Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials | 2.4 | 250 | Citations (PDF) |
| 248 | Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765) | 2.4 | 57 | Citations (PDF) |
| 249 | Comparison of pegfilgrastim on day 2 vs. day 4 as primary prophylaxis of intense dose-dense chemotherapy in patients with node-positive primary breast cancer within the prospective, multi-center GAIN study: (GBG 33) | 2.2 | 25 | Citations (PDF) |
| 250 | 0157 GAIN study: A phase III trial to compare ETC vs. EC-TX and ibandronate vs. observation in patients with node-positive primary breast cancer | 2.3 | 1 | Citations (PDF) |
| 251 | Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy | 4.8 | 99 | Citations (PDF) |
| 252 | Neoadjuvant breast cancer therapy: the German experience | 0.5 | 1 | Citations (PDF) |
| 253 | Clinical feasibility of (neo)adjuvant taxane-based chemotherapy in older patients: analysis of >4,500 patients from four German randomized breast cancer trials | 4.8 | 46 | Citations (PDF) |
| 254 | Neoadjuvant Vinorelbine-Capecitabine Versus Docetaxel-Doxorubicin-Cyclophosphamide in Early Nonresponsive Breast Cancer: Phase III Randomized GeparTrio Trial | 4.6 | 282 | Citations (PDF) |
| 255 | Intensified Neoadjuvant Chemotherapy in Early-Responding Breast Cancer: Phase III Randomized GeparTrio Study | 4.6 | 241 | Citations (PDF) |
| 256 | Rolle der Peritonealkarzinose (PC) Im Rahmen der Operation eines Ovarialkarzinomrezidivs (SROC) – DESKTOP I–Studie: Rolle der Peritonealkarzinose | 0.4 | 0 | Citations (PDF) |
| 257 | Nachweis zirkulierender Tumorzellen (CTC) unter primär systemischer Chemotherapie (PST) im Rahmen der GeparQuattro-Studie | 0.4 | 0 | Citations (PDF) |
| 258 | GYN 4: phase I study of BIBF 1120 in combination with paclitaxel/carboplatin in patients with advanced gynecological malignancies | 0.4 | 0 | Citations (PDF) |
| 259 | Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum–taxane based therapy—A phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6)☆ | 3.0 | 89 | Citations (PDF) |
| 260 | Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the Arbeitsgemeinschaft Gynäekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and Kommission Uterus (AGO-K-Ut) | 3.0 | 62 | Citations (PDF) |
| 261 | Onkologie - Medikamentöse Prävention des Mammakarzinoms | 0.0 | 0 | Citations (PDF) |
| 262 | Darbepoetin Alfa as Primary Prophylaxis of Anemia in Patients with Breast Cancer Treated Preoperatively with Docetaxel/Doxorubicin/Cyclophosphamide | 1.1 | 4 | Citations (PDF) |
| 263 | Investigations on the inducible and endothelial nitric oxide synthases in human breast cancer cell line MCF-7 – estrogen has an influence on e-NOS, but not on i-NOS | 2.9 | 21 | Citations (PDF) |
| 264 | Surgical Procedures After Neoadjuvant Chemotherapy in Operable Breast Cancer: Results of the GEPARDUO Trial | 2.3 | 85 | Citations (PDF) |
| 265 | Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial | 2.3 | 401 | Citations (PDF) |
| 266 | Stadienadaptierte Therapie des Mammakarzinoms | 0.1 | 1 | Citations (PDF) |
| 267 | ZEN-008: eine Phase I Studie mit einem zytotoxischen GnRH-Analogon (AN-152) bei Patientinnen mit fortgeschrittenen, GnRH-Rezeptor I exprimierenden Karzinomen | 0.4 | 0 | Citations (PDF) |
| 268 | VEGF-A und COX-2 Expression korrelieren mit der Platinresistenz beim Ovarial-Ca | 0.4 | 0 | Citations (PDF) |
| 269 | Paclitaxel-carboplatin-gemcitabine (TCG) versus paclitaxel-carboplatin (TC) as first line treatment in women with ovarian cancer: A randomized phase III GCIG Intergroup study (AGO-OVAR 9, GINECO-TCG, NSGO-OC-0102) | 0.4 | 1 | Citations (PDF) |
| 270 | Venlafaxin ist Clonidin in der Behandlung von Hitzewallungen bei Brustkrebspatientinnen überlegen–eine doppelblinde randomisierte Studie | 0.4 | 0 | Citations (PDF) |
| 271 | Verminderung von Komplikationen sowie Pflege implantierter Portkatheter bei Tumorpatienten | 0.0 | 0 | Citations (PDF) |
| 272 | Weekly Carboplatin Combination Therapy is Also More Effective in Platinum-Resistant Ovarian Cancer | 2.7 | 0 | Citations (PDF) |
| 273 | Das Mammakarzinom | 0.1 | 0 | Citations (PDF) |
| 274 | Phase I/II study of capecitabine and vinorelbine in pretreated patients with metastatic breast cancer | 10.0 | 64 | Citations (PDF) |
| 275 | Use of goserelin in the treatment of breast cancer | 2.5 | 17 | Citations (PDF) |
| 276 | In vivo chemosensitivity adapted preoperative chemotherapy in patients with early stage breast cancer: the Gepartrio pilot study | 10.0 | 1 | Citations (PDF) |
| 277 | The role of early expression of inducible nitric oxide synthase in human breast cancer | 5.0 | 95 | Citations (PDF) |
| 278 | Clonidin vs. Venlafaxin als Behandlung von Hitzewallungen bei Patientinnen mit Mammakarzinom – eine doppelblinde randomisierte Studie | 0.0 | 0 | Citations (PDF) |
| 279 | 000197: THE ANTI-IDIOTYPIC MONOCLONAL ANTIBODY ACA125 IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PERITONEAL CANCER. A PHASE II TRIAL OF THE AGO-OVAR | 2.7 | 0 | Citations (PDF) |
| 280 | Silencing of the HER2/neu Gene by siRNA Inhibits Proliferation and Induces Apoptosis in HER2/neu-Overexpressing Breast Cancer Cells | 7.0 | 122 | Citations (PDF) |
| 281 | E10. Breast cancer during pregnancy | 0.5 | 3 | Citations (PDF) |
| 282 | 003 Epirubicin/Paclitaxel/Carboplatin (TEC) Versus Paclitaxel/Carboplatin (TC) in First-Line Treatment of Ovarian Cancer Figo Stages IIB-IV. Mature Results of A Randomized AGO-GINECO GCIG Intergroup Phase III Trial | 2.7 | 0 | Citations (PDF) |
| 283 | 228 Pegliposomal Doxorubicin (PLD) and Carboplatin (C) for Gynaecological Tumours – Phase I/II-Study From The Ago Ovarian Cancer Study Group | 2.7 | 0 | Citations (PDF) |
| 284 | 100 Gefinitib in Combination With Tamoxifen in Patients With Ovarian Cancer Refractory to Platinum-Taxane Based Therapy – A Phase II Study of The Ago Ovar | 2.7 | 0 | Citations (PDF) |
| 285 | EGF-R and Her2/neu overexpressing tumors: independent collectives for treatment of breast cancer by specific monoclonal antibody-therapy | 2.3 | 4 | Citations (PDF) |
| 286 | Mammakarzinom in der Schwangerschaft – eine Registerstudie zur Verbesserung der Therapie für Mutter und Kind | 0.4 | 0 | Citations (PDF) |
| 287 | Anti-epidermal growth factor receptor-antibody therapy for treatment of breast cancer | 4.3 | 19 | Citations (PDF) |
| 288 | Expression of endothelial and inducible nitric oxide synthase in benign and malignant lesions of the breast and measurement of nitric oxide using electron paramagnetic resonance spectroscopy | 4.0 | 79 | Citations (PDF) |
| 289 | Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells | 6.5 | 154 | Citations (PDF) |
| 290 | Title is missing! 2002 | | 2 | Citations (PDF) |
| 291 | Predictive value of serum interleukin-6 and -8 levels in preterm labor or rupture of the membranes | 2.6 | 58 | Citations (PDF) |
| 292 | AGO Breast Commission recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2025 | 0.9 | 9 | Citations (PDF) |
| 293 | Supplementation of Tamoxifen with Low-Dose Endoxifen in Patients with Breast Cancer with Impaired Tamoxifen Metabolism (TAMENDOX): A Randomized Controlled Phase I/II Trial | 6.8 | 2 | Citations (PDF) |
| 294 | Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer | 10.0 | 17 | Citations (PDF) |
| 295 | A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib’s Journey from Discovery to Approval and What’s Next in CDK Inhibition in Breast Cancer | 3.2 | 1 | Citations (PDF) |
| 296 | Molekulare Heterogenität des HR+/HER2– Mammakarzinoms: Von klassisch zu adaptiv – neue Möglichkeiten der Subtypisierung 0, , | | 0 | Citations (PDF) |
| 297 | Molekulare Testungen zu therapeutischen Zwecken bei Brustkrebs – Hilfe für die klinische Praxis | 0.4 | 0 | Citations (PDF) |
| 298 | Preoperative immunotherapy in oncology | 0.1 | 1 | Citations (PDF) |
| 299 | Molekulare Heterogenität des HR+/HER2– Mammakarzinoms: Von klassisch zu adaptiv – neue Möglichkeiten der Subtypisierung 0, , | | 0 | Citations (PDF) |
| 300 | Abstract PS5-03-09: Trial in progress: A phase 2/3 trial of iza-bren (BMS986507/BL-B01D1), an EGFRxHER3 antibody-drug conjugate, vs standard-of-care chemotherapy in patients with previously untreated, locally advanced, recurrent inoperable, or metastatic triple negative breast cancer ineligible for anti-PD-(L)1 treatment (IZABRIGHT-Breast01) | 6.8 | 0 | Citations (PDF) |
| 301 | Molekulare Testungen zu therapeutischen Zwecken bei Brustkrebs – Hilfe für die klinische Praxis | 0.0 | 0 | Citations (PDF) |
| 302 | Lymph node surgery and CDK4/6 inhibitors in early breast cancer: a pooled analysis from five randomised trials | 27.4 | 0 | Citations (PDF) |
